The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Belantamab mafodotin for RRMM: Real-world data from the ALFA study
|
The noninterventional, retrospective ALFA study assessed the real-world safety and efficacy of belantamab mafodotin, a B-cell maturation agent (BCMA)-targeted antibody–drug conjugate, in adult patients with relapsed/refractory multiple myeloma (RRMM).1 The study included 184 patients treated with belantamab mafodotin monotherapy in 45 centers in France from April 2020 to June 2021. Results were published in the European Journal of Haematology by Roussel et al.1 |
| Key learnings: |
|
The overall response rate was 32.7%, with 20.4% and 12.3% of patients achieving at least a very good partial response (≥VGPR) and partial response, respectively, consistent with clinical trial data. Response rates were consistent across subgroups. |
|
Median progression-free survival (PFS) and overall survival (OS) were 2.4 months and 8.8 months, respectively. Notably, patients who responded to treatment had significantly improved survival outcomes, with a median PFS and OS of 20.6 months and not reached, respectively, in patients achieving ≥VGPR, underscoring the importance of response depth in patient outcomes. |
|
The safety profile highlighted that 86.4% of patients experienced adverse events (AEs), primarily ocular (56.0%), including keratopathy (41.8%), which was manageable with appropriate ophthalmological monitoring and interventions. |
|
These findings affirm that belantamab mafodotin can be effectively and safely used in routine clinical practice in a broad range of patients with RRMM, irrespective of their characteristics, though careful management of ocular AEs is necessary. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
